Schaeffers Research·Sep 16, 2026
Most Active Options Report: FPS, TEVA, AFLThese three stocks are seeing some of the most unusual options volume today
Teva's operational turnaround, evidenced by gross margin expansion from 46.4% in 2024Q1 to 52.0% in 2026Q2 and a return to profitability in 2025, suggests improving fundamentals. However, the 2026Q2 net loss of -$576M and operating margin collapse to 3.6% indi...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth stalled at -0.8% in 2026Q2, yet gross margin improved to 52.0% from 46.4% in 2024Q1, though operating margin collapsed to 3.6% in 2026Q2 from a peak of 19.7% in 2025Q3.
Teva's transition from generics to innovative treatments, driven by products like Austedo, Ajovy, and Uzedy, is a key growth driver.
Products such as Austedo and Ajovy are experiencing strong growth, contributing significantly to Teva's revenue.
Under CEO Francis, Teva has implemented operational improvements, enhancing efficiency and profitability.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.02-75.0% vs $0.08 | $4.1B+1.5% vs $4.1B |
Q2 2026 Apr 29, 2026 | $0.53+6.0% vs $0.50 | $4.0B+5.1% vs $3.8B |
Q1 2026 Jan 28, 2026 | $0.96+47.7% vs $0.65 | $4.7B+9.1% vs $4.3B |
Q4 2025 Nov 5, 2025 | $0.78+14.7% vs $0.68 | $4.5B+0.6% vs $4.5B |
These three stocks are seeing some of the most unusual options volume today
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Takeda Pharmaceutical has a
Teva Pharmaceutical Industries (NYSE: TEVA) said its "Pivot to Growth" strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet. Speaking at a Morgan Stanley event, President and Chief Executive Officer Richard Francis said the company began the
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) had a busy week that included a major debt refinancing, a milestone shift in how its shares trade on the NYSE and analyst activity.
Benchmark TEVA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Teva Pharmaceutical Industries Limited (TEVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $39.52 | $46.67B | 32.93 | 4.31% | 8.17% | 20.68% | — | |
| $17.18 | $20.01B | -5.73 | -2.98% | -2.79% | -2.79% | — | |
| $14.31 | $1.98B | -1.39 | -2.75% | -41.85% | -55.97% | — | |
| $19.50 | $6.23B | 88.64 | 8.05% | 5.05% | — | — | |
| $43.75 | $2.54B | -64.34 | 8.63% | -13.23% | -10.42% | — | |
| $100.00 | $6.51B | 29.33 | 0.5% | 17.69% | 23.27% | — |
Teva Pharmaceutical Industries Limited (TEVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Teva Pharmaceutical Industries Limited (TEVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
May 28, 2026·SEC
Apr 29, 2026·SEC
Get notified when TEVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Teva Pharmaceutical Industries Limited (TEVA) stock FAQ — growth, dividends, profitability & financials explained
Teva Pharmaceutical Industries Limited (TEVA) reported $17.31B in revenue for fiscal year 2025. This represents a 1715% increase from $953.8M in 1996.
Teva Pharmaceutical Industries Limited (TEVA) grew revenue by 4.3% over the past year. Growth has been modest.
Yes, Teva Pharmaceutical Industries Limited (TEVA) is profitable, generating $706.0M in net income for fiscal year 2025 (8.2% net margin).
Teva Pharmaceutical Industries Limited (TEVA) has a return on equity (ROE) of 20.7%. This is excellent, indicating efficient use of shareholder capital.
Teva Pharmaceutical Industries Limited (TEVA) generated $1.76B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
